Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin-like growth factor 1-ultrasmall iron oxide nanoparticle + SN-38
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
IGF1-uIONP/SN38 is an experimental nanoparticle-based drug delivery system designed for the targeted treatment of pancreatic cancer. It consists of ultrafine iron oxide nanoparticles (uIONP) conjugated with insulin-like growth factor 1 (IGF1) as a targeting ligand and loaded with SN-38, the potent active metabolite of the chemotherapy drug irinotecan. The platform leverages the overexpression of the insulin-like growth factor 1 receptor (IGF1R) in pancreatic cancer cells for active targeting. Upon receptor-mediated internalization, the system utilizes a pH-responsive mechanism to release SN-38 in the acidic environment of the tumor interstitium and lysosomes. SN-38 acts as a topoisomerase I inhibitor, inducing DNA damage and apoptosis in cancer cells. This theranostic platform aims to overcome the delivery barriers posed by the dense stroma of pancreatic tumors while providing potential for imaging applications through the iron oxide core.
- Other names
- IGF1-uIONP/SN38IGF1-uIONP-SN38IGF-1-uIONP-SN38IGF 1-uIONP-SN38
02
Targets
TOP1 (DNA Topoisomerase I)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on insulin-like growth factor 1-ultrasmall iron oxide nanoparticle + SN-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin-like growth factor 1-ultrasmall iron oxide nanoparticle + SN-38.